- English
- Chinese
- French
- German
- Portuguese
- Spanish
- Russian
- Japanese
- Korean
- Arabic
- Irish
- Greek
- Turkish
- Italian
- Danish
- Romanian
- Indonesian
- Czech
- Afrikaans
- Swedish
- Polish
- Basque
- Catalan
- Esperanto
- Hindi
- Lao
- Albanian
- Amharic
- Armenian
- Azerbaijani
- Belarusian
- Bengali
- Bosnian
- Bulgarian
- Cebuano
- Chichewa
- Corsican
- Croatian
- Dutch
- Estonian
- Filipino
- Finnish
- Frisian
- Galician
- Georgian
- Gujarati
- Haitian
- Hausa
- Hawaiian
- Hebrew
- Hmong
- Hungarian
- Icelandic
- Igbo
- Kannada
- Kazakh
- Khmer
- Kurdish
- Kyrgyz
- Latin
- Latvian
- Lithuanian
- Luxembou..
- Macedonian
- Malagasy
- Malay
- Malayalam
- Maltese
- Maori
- Marathi
- Mongolian
- Burmese
- Nepali
- Norwegian
- Pashto
- Persian
- Punjabi
- Serbian
- Sesotho
- Sinhala
- Slovak
- Slovenian
- Somali
- Samoan
- Scots Gaelic
- Shona
- Sindhi
- Sundanese
- Swahili
- Tajik
- Tamil
- Telugu
- Thai
- Ukrainian
- Urdu
- Uzbek
- Vietnamese
- Welsh
- Xhosa
- Yiddish
- Yoruba
- Zulu
- Kinyarwanda
- Tatar
- Oriya
- Turkmen
- Uyghur
Dr Yu Baofa lan tim saka Amerika Serikat nerbitake artikel ing Journal of Gastroenterology Research and Practice
2025-02-11
Dokter Yu Baofa lan tim Amerika bareng-bareng nerbitake artikel Evaluasi macem-macem autoantibodies menyang antigen sing gegandhengan karo tumor minangka tandha diagnostik potensial kanggo kanker pankreas ing Jurnal Riset lan Praktek Gastroenterologi.
Tujuan saka panliten iki yaiku kanggo ngevaluasi signifikansi klinis autoantibodi marang GNA11, MSLN, GNAS, CEBPA, MDM2, p16, Sui1, Calnuc, PTEN ing kanker pankreas (PC). Gunggunge 33 conto serum saka pasien PC lan 45 conto serum saka kontrol normal (NC) kalebu, lan 9 jinis autoantibodi dideteksi nggunakake enzim-linked immunosorbent assay (ELISA). Evaluasi nggunakake macem-macem paramèter ing wangun individu utawa gabungan. Kajaba anti GNAS lan anti calNUC, tingkat kabeh autoantibodi liyane luwih dhuwur tinimbang sing ana ing klompok kontrol normal. Dibandhingake karo klompok kontrol normal (4,9%), frekuensi saka papat autoantibodies, MSLN, p16, PTEN, lan Sui1, mundhak sacara signifikan, ing 75,8%, 66,7%, 30,3%, lan 27,3%. Kemampuan autoantibodi iki kanggo mbedakake area ing kurva ROC (AUC) antara 0.666 nganti 0.884, kanthi anti-p16 (AUC saka 0.884) lan anti MSLN (AUC saka 0.857) nuduhake kinerja diagnostik sing paling kuat. Kombinasi anti-MSLN lan anti-p16 bisa nambah sensitivitas diagnosis.
Kajaba iku, autoantibodi MSLN lan Sui1 mudhun ing pasien PC sawise kemoterapi. Papat autoantibodies marang MSLN, p16, Sui1 lan PTEN nuduhake tandha diagnostik potensial kanggo kanker pankreas, sing anti MSLN lan anti p16 sing paling apik. Kombinasi saka rong autoantibodi kasebut nuduhake potensial sing paling ekonomis lan praktis. Pentinge nyuda autoantibodi marang MSLN lan Sui1 ing pasien PC sawise kemoterapi mbutuhake eksplorasi luwih lanjut.
Panliten babagan autoantibodi sing gegandhengan karo tumor menehi referensi penting kanggo screening awal, diagnosis, lan perawatan tumor. Akademisi Yu Baofa ngetrapake autoantibodi tumor ing perawatan tumor luwih saka 20 taun kepungkur.
